ESR1 and breast cancer: Interfering with the ERα pathway using anti‐estrogens (selective estrogen receptor modulators), such as tamoxifen (Tam), or estrogen deprivation (e.g., aromatase inhibitors—AI), increases the survival of ERα‐positive BC patients.